Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

High-yielding healthcare stocks GSK, DENTSPLY SIRONA, and Bristol-Myers Squibb are facing increased analyst scrutiny, with several firms issuing downgrades or reducing price targets. GSK saw multiple analyst downgrades concurrent with a CEO designate announcement, while DENTSPLY SIRONA received mixed ratings and price target cuts following a strategic retention decision. Bristol-Myers Squibb also experienced price target reductions despite reporting positive Phase 3 trial results, indicating a cautious outlook among analysts for these dividend-payers.

Analysis

Despite the appeal of high-dividend stocks in turbulent markets, recent analyst actions on three healthcare companies—GSK, DENTSPLY SIRONA, and Bristol-Myers Squibb—signal significant caution. GSK (4.13% yield) received two downgrades from Buy to Hold/Neutral by analysts from Jefferies and Guggenheim, with the latter analyst possessing a high 73% accuracy rate; this coincides with the announcement of a CEO designate, suggesting potential uncertainty during the leadership transition period into 2026. DENTSPLY SIRONA (5.04% yield) saw its price target cut by both UBS and Stifel, with Stifel's reduction being particularly sharp from $19 to $17, following the company's decision to retain its Wellspect Healthcare unit. This indicates that the market is tempering expectations post-strategic review. Most notably, Bristol-Myers Squibb (5.62% yield) faced price target reductions and a maintained Underweight rating from Morgan Stanley, even after announcing positive Phase 3 results for its iberdomide treatment. This divergence suggests that analysts' broader concerns are currently outweighing specific positive pipeline developments.

Key Decisions for Investors

• Given the consistent analyst downgrades and price target cuts across these high-yield healthcare names, investors should scrutinize the fundamental headwinds and not treat the dividend yield as a standalone investment thesis.
• For GSK, the combination of two recent downgrades and an extended CEO transition period warrants a cautious stance, as strategic uncertainty may persist until the new leadership is fully in place in 2026.
• Investors in Bristol-Myers Squibb should investigate the underlying reasons for negative analyst sentiment, as the price target cuts despite positive clinical trial news suggest that significant structural concerns may be overshadowing pipeline progress.
• The downward price target revisions for DENTSPLY SIRONA, even from analysts with a Buy rating, signal that near-term upside may be capped following its decision to retain Wellspect Healthcare, meriting a re-evaluation of growth expectations.